JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB264688

Human RIPK2 (RIP2) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

RIPK2 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 2 bp deletion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
3 Images
Western blot - Human RIPK2 (RIP2) knockout HeLa cell line (AB264688)
  • WB

Lab

Western blot - Human RIPK2 (RIP2) knockout HeLa cell line (AB264688)

Lanes 1-4 : Merged signal (red and green). Green - ab75257 observed at 65 kDa. Red - loading control ab181602 observed at 37 kDa.

ab75257 Anti-RIP2 antibody [AF28D3] was shown to specifically react with RIP2 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab264688 (knockout cell lysate ab258636) was used. Wild-type and RIP2 knockout samples were subjected to SDS-PAGE. ab75257 and Anti-GAPDH antibody[EPR16891] - Loading Control (ab181602) were incubated overnight at 4° at 1 in 2000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (ab216772) and Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (ab216777) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-RIP2 antibody [AF28D3] (<a href='/en-us/products/primary-antibodies/rip2-antibody-af28d3-ab75257'>ab75257</a>) at 1/2000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

RIPK2 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human RIPK2 (RIP2) knockout HeLa cell line (ab264688)

Lane 3:

Ramos cell lysate at 20 µg

Lane 4:

Jurkat cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-mouse-igg-h-l-irdye-800cw-preadsorbed-ab216772'>ab216772</a>) at 1/20000 dilution

Predicted band size: 61 kDa

Observed band size: 65 kDa

false

Sanger Sequencing - Human RIPK2 (RIP2) knockout HeLa cell line (AB264688)
  • Sanger seq

Unknown

Sanger Sequencing - Human RIPK2 (RIP2) knockout HeLa cell line (AB264688)

Allele-1 : 2 bp deletion in exon 1.

Sanger Sequencing - Human RIPK2 (RIP2) knockout HeLa cell line (AB264688)
  • Sanger seq

Unknown

Sanger Sequencing - Human RIPK2 (RIP2) knockout HeLa cell line (AB264688)

Allele-2 : 1 bp insertion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 2 bp deletion in exon 1

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab264688-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264688 Human RIPK2 (RIP2) knockout HeLa cell line", "number":"AB264688-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255448 Human wild-type HeLa cell line", "number":"AB264688-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab264688-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255448 Human wild-type HeLa cell line", "number":"AB264688-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab264688 Human RIPK2 (RIP2) knockout HeLa cell line", "number":"AB264688-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264688-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264688 Human RIPK2 (RIP2) knockout HeLa cell line", "number":"AB264688-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264688-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264688 Human RIPK2 (RIP2) knockout HeLa cell line", "number":"AB264688-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
RIPK2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

RIP2 also known as receptor-interacting serine/threonine-protein kinase 2 or RICK is a protein with roles in signal transduction. It functions mechanically as a kinase which means it adds a phosphate group to other proteins impacting their activity and stability. RIP2 weighs about 61 kDa and is mostly expressed in immune system-related tissues such as spleen thymus peripheral blood leukocytes and bone marrow. As a kinase RIP2 is an action part in the cellular response to external stimuli.
Biological function summary

RIP2 interacts with key components of the immune signaling network. It forms part of a complex with other proteins like nucleotide-binding oligomerization domain (NOD) proteins influencing immune responses. By binding to NOD1 and NOD2 RIP2 modulates inflammatory signaling pathways leading to the activation of NF-kB and the production of inflammatory cytokines. This protein helps regulate the body's defense against bacterial infections and influences inflammation processes.

Pathways

RIP2 plays an integral role in the NOD-like receptor signaling pathway and is also involved in toll-like receptor signaling. In its pathways RIP2 interacts closely with proteins like IKK complexes and the Tak1 complex orchestrating signaling cascades leading to the activation of NF-kB and MAPK pathways. These pathways are essential for instigating the immune response and managing inflammatory signals highlighting how RIP2 acts as a pivotal mediator in these biological routes.

Mutations or dysregulation of RIP2 are linked to inflammatory diseases and immune disorders such as Crohn's disease and Blau syndrome. RIP2's involvement in these conditions often involves its interaction with NOD2 influencing the improper immune response seen in these diseases. Changing RIP2 activity presents a target for developing kinase inhibitors that might help to manage inflammation and immune system disorders by modulating its signaling activity.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com